CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortez...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Immunol
Главные авторы: Seckinger, Anja, Hillengass, Jens, Emde, Martina, Beck, Susanne, Kimmich, Christoph, Dittrich, Tobias, Hundemer, Michael, Jauch, Anna, Hegenbart, Ute, Raab, Marc-Steffen, Ho, Anthony D., Schönland, Stefan, Hose, Dirk
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2018
Предметы:
Immunology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6062598/
https://ncbi.nlm.nih.gov/pubmed/30079070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01676
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы